Therapix Biosciences’ (NASDAQ:TRPX) lock-up period is set to end on Monday, September 18th. Therapix Biosciences had issued 2,000,000 shares in its initial public offering on March 22nd. The total size of the offering was $12,000,000 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Separately, Ladenburg Thalmann Financial Services cut shares of Therapix Biosciences to a “buy” rating in a report on Monday, June 5th.
ILLEGAL ACTIVITY NOTICE: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/09/17/therapix-biosciences-ltd-s-lock-up-period-set-to-end-tomorrow-nasdaqtrpx.html.
Therapix Biosciences (NASDAQ:TRPX) opened at 5.74 on Friday. Therapix Biosciences has a 12-month low of $5.20 and a 12-month high of $13.19. The stock’s market cap is $19.85 million. The firm has a 50 day moving average of $5.71 and a 200-day moving average of $6.78.
Therapix Biosciences (NASDAQ:TRPX) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter. On average, analysts expect that Therapix Biosciences will post ($1.52) earnings per share for the current year.
Therapix Biosciences Company Profile
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.
Receive News & Ratings for Therapix Biosciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Therapix Biosciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.